SEED Innovations Ltd (AIM:SEED, OTC:FFRIF) portfolio company Eurox Group has started to market its pure tetrahydrocannabinol (THC) medical cannabis product Dronabinol in Germany through its deal with AMP.
Sales through German pharmacies are scheduled to begin in February 2022 following a non-exclusive marketing and distribution agreement.
Dronabinol preparations, primarily used in pain therapy, have been available under prescription in Germany since 1998 and currently represent a substantial part of the German medicinal cannabis market.
The dronabinol product category has far fewer suppliers competing for the German market than the case of cannabis flower or full-spectrum extracts.
Eurox, one of the first medical cannabis companies to produce Dronabinol that is 'Made in Germany', controls the entire supply chain from cultivation, production to distribution.
Ed McDermott, SEED's chief executive, said: "The latest announcement with AMP strengthens the position of Eurox as one of Europe's leading medical cannabis companies and allows further access to the German pharmaceutical and health market for Eurox's 'Made in Germany' products."
SEED has an 8.85% shareholding in Eurox.